AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Marketbeat

Published November 9, 2026

Compass Pathways' (CMPS) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Read the full story at Marketbeat

Hedge Funds Weigh In On Compass Pathways. Magic Mushrooms , Hard Cash: Compass Pathways' Trial Win, Fast Raise. Institutional investors have recently.

Post on X

Share this story

Surfaced by this Google Alert

Magic mushrooms